Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,054,621
  • Shares Outstanding, K 115,558
  • Annual Sales, $ 306,490 K
  • Annual Income, $ 94,180 K
  • 60-Month Beta 0.72
  • Price/Sales 6.67
  • Price/Cash Flow 20.92
  • Price/Book 4.51
Trade CORT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.21
  • Number of Estimates 3
  • High Estimate 0.23
  • Low Estimate 0.19
  • Prior Year 0.22
  • Growth Rate Est. (year over year) -4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.42 +8.28%
on 09/24/20
19.15 -7.13%
on 10/14/20
-0.21 (-1.17%)
since 09/18/20
3-Month
12.20 +45.74%
on 08/27/20
23.48 -24.28%
on 09/02/20
+0.91 (+5.39%)
since 07/20/20
52-Week
9.70 +83.30%
on 03/23/20
23.48 -24.28%
on 09/02/20
+4.08 (+29.73%)
since 10/18/19

Most Recent Stories

More News
Are These The Top Pharmaceutical Stocks To Buy In October 2020?

Looking for long-term buys for your portfolio? Take a look at these 3 top pharmaceutical stocks.

CORT : 17.78 (+0.45%)
JNJ : 144.55 (+0.16%)
PFE : 37.49 (-0.82%)
MNTA : 52.48 (-0.02%)
BNTX : 94.35 (+0.46%)
SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Corcept Therapeutics Incorporated (CORT) and Encourages Long-Term CORT Stockholders to Contact the Firm

, /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) on behalf of the company's stockholders. 

CORT : 17.78 (+0.45%)
Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.

MRK : 78.27 (-0.51%)
NVS : 85.69 (-0.12%)
BMY : 60.64 (-0.21%)
CORT : 17.78 (+0.45%)
Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 17.78 (+0.45%)
Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.

CORT : 17.78 (+0.45%)
Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc.

Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of Corcept Therapeutics, Inc. ("Corcept" or the "Company") (Nasdaq: CORT)....

CORT : 17.78 (+0.45%)
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

MRK : 78.27 (-0.51%)
BMY : 60.64 (-0.21%)
BLRX : 1.5700 (-0.63%)
CORT : 17.78 (+0.45%)
Corcept: 2Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported second-quarter profit of $28.3 million.

CORT : 17.78 (+0.45%)
Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 17.78 (+0.45%)
Noteworthy Monday Option Activity: CORT, CWH, HELE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Corcept Therapeutics Inc , where a total of 6,472 contracts have traded so far, representing...

CORT : 17.78 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 18.41
1st Resistance Point 18.09
Last Price 17.78
1st Support Level 17.56
2nd Support Level 17.35

See More

52-Week High 23.48
Fibonacci 61.8% 18.22
Last Price 17.78
Fibonacci 50% 16.59
Fibonacci 38.2% 14.96
52-Week Low 9.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar